Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of West Pharmaceutical Services, Inc. NYSE: WST. In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in West Pharmaceutical Services stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
- Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
- Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
- Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
- Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
- Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.
West Pharmaceutical Services Trading Up 0.6 %
Shares of WST traded up $1.32 during mid-day trading on Wednesday, reaching $221.48. 359,285 shares of the company were exchanged, compared to its average volume of 950,311. The business has a 50 day simple moving average of $259.25 and a two-hundred day simple moving average of $296.71. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.23 and a current ratio of 2.79. The stock has a market capitalization of $16.01 billion, a PE ratio of 33.11, a PEG ratio of 6.74 and a beta of 1.09. West Pharmaceutical Services, Inc. has a 52 week low of $197.01 and a 52 week high of $396.75.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.07. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. The firm had revenue of $748.80 million during the quarter, compared to analyst estimates of $739.59 million. On average, analysts predict that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.
West Pharmaceutical Services Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 7th. Stockholders of record on Wednesday, April 30th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, April 30th. This represents a $0.84 annualized dividend and a dividend yield of 0.38%. West Pharmaceutical Services's payout ratio is 12.56%.
Institutional Investors Weigh In On West Pharmaceutical Services
Several hedge funds and other institutional investors have recently made changes to their positions in WST. Bank of New York Mellon Corp boosted its stake in West Pharmaceutical Services by 6.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,449,811 shares of the medical instruments supplier's stock valued at $1,130,020,000 after purchasing an additional 203,198 shares during the last quarter. State Street Corp lifted its holdings in shares of West Pharmaceutical Services by 0.3% in the third quarter. State Street Corp now owns 3,214,448 shares of the medical instruments supplier's stock valued at $964,850,000 after purchasing an additional 10,060 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in shares of West Pharmaceutical Services by 1.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,110,903 shares of the medical instruments supplier's stock valued at $1,019,007,000 after buying an additional 44,376 shares during the last quarter. Brown Advisory Inc. grew its holdings in West Pharmaceutical Services by 11.7% during the fourth quarter. Brown Advisory Inc. now owns 2,552,036 shares of the medical instruments supplier's stock worth $835,945,000 after buying an additional 266,488 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in West Pharmaceutical Services by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 1,778,940 shares of the medical instruments supplier's stock valued at $581,209,000 after buying an additional 38,757 shares during the last quarter. 93.90% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
WST has been the subject of a number of recent analyst reports. KeyCorp decreased their price target on West Pharmaceutical Services from $470.00 to $325.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Wolfe Research assumed coverage on West Pharmaceutical Services in a research note on Friday, December 13th. They set a "peer perform" rating for the company. StockNews.com downgraded West Pharmaceutical Services from a "buy" rating to a "hold" rating in a report on Thursday, February 27th. UBS Group upgraded West Pharmaceutical Services from a "neutral" rating to a "buy" rating and increased their price target for the stock from $350.00 to $390.00 in a report on Thursday, December 12th. Finally, Evercore ISI began coverage on shares of West Pharmaceutical Services in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $275.00 price objective for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $332.50.
View Our Latest Research Report on WST
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
West Pharmaceutical Services Company Profile
(
Get Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Stories
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
